These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 22605555)
1. Genotoxicity of poly(propylene imine) dendrimers. Ziemba B; Matuszko G; Appelhans D; Voit B; Bryszewska M; Klajnert B Biopolymers; 2012 Aug; 97(8):642-8. PubMed ID: 22605555 [TBL] [Abstract][Full Text] [Related]
2. In vivo toxicity of poly(propyleneimine) dendrimers. Ziemba B; Janaszewska A; Ciepluch K; Krotewicz M; Fogel WA; Appelhans D; Voit B; Bryszewska M; Klajnert B J Biomed Mater Res A; 2011 Nov; 99(2):261-8. PubMed ID: 21976451 [TBL] [Abstract][Full Text] [Related]
3. The influence of maltotriose-modified poly(propylene imine) dendrimers on the chronic lymphocytic leukemia cells in vitro: dense shell G4 PPI. Franiak-Pietryga I; Ziółkowska E; Ziemba B; Appelhans D; Voit B; Szewczyk M; Góra-Tybor J; Robak T; Klajnert B; Bryszewska M Mol Pharm; 2013 Jun; 10(6):2490-501. PubMed ID: 23641871 [TBL] [Abstract][Full Text] [Related]
4. Influence of fourth generation poly(propyleneimine) dendrimers on blood cells. Ziemba B; Halets I; Shcharbin D; Appelhans D; Voit B; Pieszynski I; Bryszewska M; Klajnert B J Biomed Mater Res A; 2012 Nov; 100(11):2870-80. PubMed ID: 22623362 [TBL] [Abstract][Full Text] [Related]
5. Poly(propylene imine) dendrimers modified with maltose or maltotriose protect phosphorothioate oligodeoxynucleotides against nuclease activity. Drzewińska J; Appelhans D; Voit B; Bryszewska M; Klajnert B Biochem Biophys Res Commun; 2012 Oct; 427(1):197-201. PubMed ID: 22995301 [TBL] [Abstract][Full Text] [Related]
6. Investigations on biodistribution of technetium-99m-labeled carbohydrate-coated poly(propylene imine) dendrimers. Agashe HB; Babbar AK; Jain S; Sharma RK; Mishra AK; Asthana A; Garg M; Dutta T; Jain NK Nanomedicine; 2007 Jun; 3(2):120-7. PubMed ID: 17572354 [TBL] [Abstract][Full Text] [Related]
7. Toxicity and proapoptotic activity of poly(propylene imine) glycodendrimers in vitro: considering their contrary potential as biocompatible entity and drug molecule in cancer. Ziemba B; Franiak-Pietryga I; Pion M; Appelhans D; Muñoz-Fernández MÁ; Voit B; Bryszewska M; Klajnert-Maculewicz B Int J Pharm; 2014 Jan; 461(1-2):391-402. PubMed ID: 24361266 [TBL] [Abstract][Full Text] [Related]
8. Interaction study between maltose-modified PPI dendrimers and lipidic model membranes. Wrobel D; Appelhans D; Signorelli M; Wiesner B; Fessas D; Scheler U; Voit B; Maly J Biochim Biophys Acta; 2015 Jul; 1848(7):1490-501. PubMed ID: 25843678 [TBL] [Abstract][Full Text] [Related]
9. The influence of maltose modified poly(propylene imine) dendrimers on hen egg white lysozyme structure and thermal stability. Ciolkowski M; Pałecz B; Appelhans D; Voit B; Klajnert B; Bryszewska M Colloids Surf B Biointerfaces; 2012 Jun; 95():103-8. PubMed ID: 22410344 [TBL] [Abstract][Full Text] [Related]
11. Effect of poly(propylene imine) glycodendrimers on β-amyloid aggregation in vitro and in APP/PS1 transgenic mice, as a model of brain amyloid deposition and Alzheimer's disease. Klementieva O; Aso E; Filippini D; Benseny-Cases N; Carmona M; Juvés S; Appelhans D; Cladera J; Ferrer I Biomacromolecules; 2013 Oct; 14(10):3570-80. PubMed ID: 24004423 [TBL] [Abstract][Full Text] [Related]
12. Maltose modified poly(propylene imine) dendrimers as potential carriers of nucleoside analog 5'-triphosphates. Szulc A; Signorelli M; Schiraldi A; Appelhans D; Voit B; Bryszewska M; Klajnert-Maculewicz B; Fessas D Int J Pharm; 2015 Nov; 495(2):940-7. PubMed ID: 26456295 [TBL] [Abstract][Full Text] [Related]
13. Sugar-modified poly(propylene imine) dendrimers as drug delivery agents for cytarabine to overcome drug resistance. Szulc A; Pulaski L; Appelhans D; Voit B; Klajnert-Maculewicz B Int J Pharm; 2016 Nov; 513(1-2):572-583. PubMed ID: 27667754 [TBL] [Abstract][Full Text] [Related]
14. Influence of different generations of poly(propylene imine) dendrimers on human erythrocytes. Mishra V; Gupta U; Jain NK Pharmazie; 2010 Dec; 65(12):891-5. PubMed ID: 21284258 [TBL] [Abstract][Full Text] [Related]
15. Structural dependence of in vitro cytotoxicity, oxidative stress and uptake mechanisms of poly(propylene imine) dendritic nanoparticles. Khalid H; Mukherjee SP; O'Neill L; Byrne HJ J Appl Toxicol; 2016 Mar; 36(3):464-73. PubMed ID: 26671548 [TBL] [Abstract][Full Text] [Related]
16. Inclusion complexes of isoflavones with two commercially available dendrimers: Solubility, stability, structures, release behaviors, cytotoxicity, and anti-oxidant activities. Zhao C; Wang Y; Su Y; Zhang H; Ding L; Yan X; Zhao D; Shao N; Ye X; Cheng Y Int J Pharm; 2011 Dec; 421(2):301-9. PubMed ID: 22001794 [TBL] [Abstract][Full Text] [Related]
17. Reducing cytotoxicity while improving anti-cancer drug loading capacity of polypropylenimine dendrimers by surface acetylation. Wang F; Cai X; Su Y; Hu J; Wu Q; Zhang H; Xiao J; Cheng Y Acta Biomater; 2012 Dec; 8(12):4304-13. PubMed ID: 22842039 [TBL] [Abstract][Full Text] [Related]
18. Investigations on the toxicological profile of functionalized fifth-generation poly (propylene imine) dendrimer. Agashe HB; Dutta T; Garg M; Jain NK J Pharm Pharmacol; 2006 Nov; 58(11):1491-8. PubMed ID: 17132212 [TBL] [Abstract][Full Text] [Related]
19. Internalization and intracellular trafficking of poly(propylene imine) glycodendrimers with maltose shell in melanoma cells. Filimon A; Sima LE; Appelhans D; Voit B; Negroiu G Curr Med Chem; 2012; 19(29):4955-68. PubMed ID: 23033945 [TBL] [Abstract][Full Text] [Related]
20. Interactions between U-937 human macrophages and poly(propyleneimine) dendrimers. Kuo JH; Jan MS; Lin YL J Control Release; 2007 Jul; 120(1-2):51-9. PubMed ID: 17537537 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]